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Abstract
There are two main types of haemophilia, classified according to deficiency: type A, 
caused by factor VIII deficiency; and type B, which is rarer and the result of a defi-
ciency in factor IX. Haemarthroses account for 80% of bleeding in haemophilic patients, 
with half of these exhibiting deformities. Repeated joint effusion leads to a local inflam-
matory response, with the formation of hyperplasic and hypertrophic cells and sub-
sequent buildup of haemosiderin. Fibroblasts proliferate and produce collagenases 
and proteinases that act on the synovium, cartilage and bone, with a decrease in the 
joint space. Another mechanism involved is the damage caused by direct action of red 
blood cells on the cartilaginous surface of the joint lining. 153-samarium was obtained 
in research reactor by neutron irradiation of 152Sm2O3 (99.4%) in the nitrate form, 152Sm(n,p)153Sm, for 30–36 h. The labelling process was performed with 40 mg of 
hydroxyapatite, according to Barboza et al. Radiochemical purity, particle size, micro-
biological tests for sterility and pyrogen were the tests applied to obtain an useful mate-
rial. The introduction of 153Sm-HA for the treatment of haemophilic arthropathy in 
large and medium joints was a safe, cost-effective, minimally invasive and effective 
procedure in controlling bleeding and pain.
Keywords: haemophilic arthropathy, radiosynovectomy, 153samarium-hydroxyapatite
1. Introduction
The treatment of joints using radioactive material began in the 1950s, more specifically in 
1952, with chromic phosphate P32 [10]. It was initially aimed at joint involvement caused 
by rheumatoid arthritis and, to a lesser degree, pigmented villonodular synovitis, anky-
losing spondylitis, collagenosis and psoriatic arthritis in the years that followed [24]. 
With the advent of longer follow-up studies, it has also benefitted rheumatic diseases and 
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haemophilic arthropathy, which exhibit a similar sequence of events including repetitive 
intra-articular haemorrhages causing synovitis, joint pain, limited mobility and posterior 
muscular atrophy. Recurrent synovitis results in cartilage destruction, progressive loss of 
movement, joint deformities, bone damage and ultimately total ankylosis. The treatment 
procedure was originally denominated synovectomy (from the Greek ‘ectomía’ meaning 
‘to cut out’) and later synoviorthesis (from the Greek word ‘orthesis’ meaning ‘restora-
tion’) via radionuclides [8].
Different radioactive materials have been used to eradicate synovitis, some emitting only beta 
radiation and others beta and gamma radiation. Synovectomy in haemophilia using radioac-
tive material began in 1971 [1]. Since then, a variety of materials have been used, including 
P32, colloidal 198Au, 186Re, 90Y, 165Dy, 166Ho, and 169Er. Table 1 shows the characteristics 
of the materials used [1, 12, 16–18, 21, 28].
Irradiation occurs via the intra-articular retention of the radioactive material. However, it 
should be noted that the radioactive material is bound to larger particles, known as carri-
ers, which undergo phagocytosis by the macrophages in the inflammatory process, favour-
ing greater retention in the joint space. These macrophages migrate through the interstice of 
synovial cell layers, resulting in more homogeneous action by the ionising radiation. This 
behaviour was highlighted in autoradiographic studies [7], which more clearly indicate the 
location of samarium-153 particulate at different synovial tissue depths than other materials 
used, such as 186Re. This is also reported by Schneider et al. [23] (shown in Figure 1), in addi-
tion to direct irradiation by the intra-articular radionuclide. As such, average penetration is 
ascertained by the range of the β particle and maximum penetration by macrophage perme-
ation into synovial cell layers.
Radioisotopes Half-life 
(days)
Max. beta 
energy (MeV)
Gamma energy 
(KeV)
Penetration (mm) Particle size 
(μm)
Leakage (%)
Max. Av.
Colloidal 198Au 2.7 0.96 110 3.6 1.2 0.02–0.04 20–35
P32 (chromic 
phosphate)
14.0 1.7 – 7.9 2.6 0.05–0.1 2–4
186Re (sulphide 
colloid)
3.75 1.07 140 3.6 1.2 0.05–0.1 2
Colloidal 90Y 2.7 2.2 – 10.8 3.8 1.5–3.5 3
166Ho (FHMA) 1.2 1.85 81 8.7 2.2 1.82–12 1
165Dy (FHMA) 0.095 1.3 95 5.6 1.4 0.8–12 1
169Er (citrate) 9.4 0.34 – 1.0 0.3 0.1–10 1
153Sm (HA) 1.95 0.80 100 3.1 0.8 1–10 0.1
FHMA = ferric hydroxide macroaggregates.
Table 1. Characteristics of the radioisotopes used in synovectomy.
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Another noteworthy aspect is that radionuclide leakage from the joint is inversely pro-
portional to particle size. This is clearly evident in the last two columns of Table 1. The 
presence of gamma radiation allows synovectomy to be monitored over several days via 
scintigraphy.
2. Haemophilic arthropathy
Haemophilia is a congenital bleeding disorder linked to the X chromosome of the human 
genome, with the two most common types being haemophilia A, a lack of blood clot-
ting factor VIII, and haemophilia B, caused by missing of defective factor IX. Joint bleed-
ing associated with muscle bleeding represents 90% of bleeding episodes in haemophilia 
patients, while haemarthrosis alone accounts for 70–80% of these episodes. In 80% of 
cases, haemarthrosis occurs in the knees, elbows and ankles [22], producing inflammatory 
changes in the synovial membrane. Recurrence of this inflammation over time triggers a 
chain of events that lead to joint ankylosis, including the direct damage of blood on the 
articular cartilage [15].
In cases of arthropathy mediated by reactive synovitis, synovectomy with radioactive mate-
rial is an alternative to intra-articular injection of glucocorticoids and other chemical agents 
(osmic acid, collagenase, rifocin and thiotepa) or surgery. Furthermore, radiosynovectomy, 
introduced by Ahlberg in the 1970s, has been proposed as a first-line treatment option for 
haemophilic arthropathy [22, 23].
A B 
Figure 1. (A) β-Emitting colloidal particles (yellow stars) phagocytised by inflamed hypertrophic synovial lining with 
proliferating synoviocytes (pink). The cartilage layer remains unaffected. (B) Subsequent cell damage and sclerosis of 
synovial membrane.
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3. 153Samarium-hydroxyapatite
153-samarium was obtained in an IEA-R1 research reactor (IPEN-CNEN, São Paulo, Brazil) 
by neutron irradiation of 152Sm2O3 (99.4%) in the nitrate form, 152Sm(n,p)153Sm, for 30–36 h. The labelling process was performed with 40 mg of hydroxyapatite, using appropriately sized 
particles (20 μm), according to Barboza et al. [2]. Percentage bound activity or labelling effi-
ciency was determined by centrifugation, measuring the activity of the precipitate (153Sm-HA) 
and supernatant (153Sm-free) using a dose calibrator, and was always >90%. Radiochemical 
purity was higher than 98%, measured using Whatman 3MM paper chromatography (from 
GE, Milwaukee, WI, USA) in 0.9% saline, remaining stable for 24 h. Particle size was deter-
mined by laser scattering and filtration in a filter system of known sizes (1–15 μm), with a 
mean of 10 μm (range: 3–12 μm). Microbiological tests for sterility and pyrogen were always 
negative in all samples.
4. Patient selection
Participants were haemophilic patients with chronic synovitis, monitored at the Department 
of Haematology – Hospital de Apoio in the Federal District (DF), and the Orthopaedics and 
Nuclear Medicine Service of the Hospital de Base (DF), between 2002 and 2011.
Patients were assessed by clinical history and a physical examination, paying special atten-
tion to the compromised joint. Particular emphasis should be given to haematology tests in 
order to characterise the type and severity of haemophilia, as well as the absence of coagula-
tion inhibition factors. Imaging (radiology) tests make it possible to determine the degree 
of arthropathy, with the Pettersson score being widely used. Three-phase whole-body scans 
are used to identify any other joints involved and more accurately characterise the synovial 
inflammatory process. Other procedures used for this purpose include ultrasound or mag-
netic resonance imaging (particularly for the knees).
Inclusion criteria were the following: chronic synovitis when occurs repetitive effusions (min-
imum: once a month), pain on joint palpation and absence of other joint disease, like the 
rheumatologic or orthopaedic nature. Exclusion criteria were ruptured Baker’s cyst, major 
effusions, signs of acute synovitis or presence of an articular or periarticular infectious process.
5. Procedure
Synovectomy of the radioactive material was made by an orthopaedist with previous use of 
the deficient clotting factor, applying topical anaesthesia in accordance with the asepsis and 
antisepsis performances used for invasive intra-articular orthopaedic procedures. The use of 
ultrasound to guide the punctures was not necessary, as these were assured by the aspiration 
of synovial fluid before administration of the radionuclide (Figure 2). Fixed doses of 5 mCi 
(185 MBq) or 20 mCi (740 MBq) of 153Sm-hydroxyapatite were used, with only one injection 
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administered per patient. The maximum volume of radioactive material was 0.5 mL; material 
adhered to the puncture site was washed away with saline, at fractions of 0.5 mL, without 
exceeding the final volume of 1.5–2.0 mL.
The reflux and homogeneity (or lack thereof) of the intra-articular material and its escape 
from the joint were monitored by a scintigraphic study in a gamma camera, with a wide field 
of vision detector and low-energy collimator. Imaging was made using a 128-pixel matrix and 
the spectrometer window was centred at 100 keV, using precocious, 1 and 2 h, and later times, 
3–7 days, after 153Sm-HA injection. A summary of this protocol is shown in Table 2.
Figure 2. Injection of the knee.
1 Use a coagulation factor before the procedure;
2 Local asepsis;
3 Use local anaesthetic;
4 Joint puncture using a 21G needle;
5 Aspirate synovial fluid;
6 Inject 5 mCi of 153Sm-HA into the intermediate joints and 20 mCi into the knees;
7 Wash the puncture site with a total of 2.0 mL of saline without using corticosteroids;
8 Compression bandaging using crepe bandage;
9 Monitor the material used in the puncture;
10 Functionally permissible joint mobility;
11 Immediate (1–2 hours after synovectomy) and later (3–7 days) scintigraphy image
Table 2. Protocol for synovectomy with 153Sm-hydroxyapatite.
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6. Side effects
Reactive synovitis may occur in the days following application of the radiopharmaceutical 
agent, which was treated using conservative measure such as joint rest, local application of ice 
and a non-steroid anti-inflammatory agent. The cases observed in our study were mild and 
occurred in 4–8% of joints.
Radionecrosis may occur if the material leaks from the administration route. This complica-
tion did not occur in the cases we treated because the material was only administered after 
correct injection and the puncture site was washed with saline to prevent leakage.
Immobilisation of the affected limb will ultimately result in thrombosis; however, this was 
prevented by the protocol used.
There is no concern about possible carcinogenic effects of this procedure. Systemic irradiation 
can result from fluid leakage or the gamma component of 153Sm. Studies on chromosomal 
abnormalities in circulating lymphocytes related to samarium [19] have shown no definitive 
changes, but rather transient and reversible ones. It is important to note that this irradiation 
is smaller than in diagnosis by conventional bone scintigraphy or whole-body scanning with 
67Ga. Considering the local effect at joint level, several studies with long follow-up times 
have shown no occurrence of tumours [14, 26, 27], indicating that this possibility has not yet 
been characterised.
7. Synovectomy
The first study was conducted to evaluate the efficiency of treatment with 153-samarium 
hydroxyapatite (153-Sm-HA) in haemophilic arthropathy. Thirty-one patients (30 males) 
between 8 and 34 years old (medium age = 20.6 years) were treated with a fixed intra-articular 
dose of 5 mCi (185 MBq) and divided into two groups: paediatric (13 patients aged up to 
18 years, with a medium age of 12.7 years and arthropathy evolution of 7.8 years); and adults 
(18 patients over 18 years old, with an average age of 24 years and arthropathy evolution 
of 18.7 years). Clinical assessment before and 1 year after synoviorthesis used the following 
criteria: subjective (pain according to the visual analogue scale, joint inspection), objective 
(joint movement through flexion level, pain to palpation and leakage through joint circumfer-
ence), reduced use of the coagulation factor, number of haemarthroses, and the occurrence 
of adverse effects. The results were classified as: 1, good (symptom remission of 70–100%); 2, 
moderate (symptom remission between 40 and 69%); and 3, poor (0–39% symptom remis-
sion). Seventy-eight joints were tested: 15 knees, 36 elbows, 24 ankles, 1 shoulder and 2 hips. 
Early (1–2 h) and late phase scintigraphic imaging (24–72 h) was made after synovectomy. No 
significant inter-group difference in synovectomy results was observed. The results obtained 
were good for 75% of elbows, 87.5% of ankles and 40% of knees; reduction in effusions and 
use of the coagulation factor were, respectively, 78% and 80% for elbows, 82% and 85% for 
ankles, and 30% and 35% for knees. Four cases of reactive synovitis were observed in the 78 
joints tested. Scintigraphy showed homogeneous distribution of the material with no leakage. 
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The introduction of 153Sm-HA in the treatment of the haemophilic arthropathy is effective for 
intermediate joints (elbows and ankles), but less so for knees. Moreover, this treatment offers 
excellent safety and is affordable [3].
The penetration of beta energy from 153samarium (153Sm) (0.8 MeV) is not only suitable for syn-
oviorthesis of intermediate joints, but can improve the radionecrosis effect using higher radio-
activity levels. The next study assessed the efficacy of 5 mCi (185 MBq) and 20 mCi (740 MBq) 
of 153-Sm hydroxyapatite (153Sm-HA) in the knees of haemophilic patients. Thirty-one patients 
(36 knees, 30 males) were divided into two groups without corticosteroid co-injection: 1 – 14 
patients (17 knees) treated with an intra-articular dose of 5 mCi of 153Sm-HA, medium age 
23 years; 2 – 17 patients (19 knees), administering 20 mCi of 153Sm-HA, medium age 21.3 years. 
Evaluation before and 1 year after synoviorthesis used the following points: reduction in the 
number of effusions and use of the coagulation factor, and increment in joint mobility. The 
occurrence of side effects was also considered. Early and late-phase scintillations studies were 
made after synovectomy and no articular immobilisation was recommended. Reduction in 
effusions and use of the coagulation factor, respectively, were: group 1 – 31.3% and 25%; group 
2 – 81.5% and 79%, with p < 0.001. No significant increment in knee mobility was observed in 
either group. Four cases of mild reactive synovitis were observed in each group. Scintigraphy 
showed homogenous distribution of the radioactive material with no leakage; the material was 
considered safe by its retention in the joint. A significant increment was observed in the synovi-
orthesis of haemophilic knees with 20 mCi of 153Sm-HA; the lower penetration of its beta radia-
tion was offset by the improved radiobiological effect when higher radioactivity is used [4].
Another study compared the use of 20 mCi (740 MBq) of 153Sm and 5 mCi (185 MBq) of 90Y, both 
labelling hydroxyapatite (HA), for knee synoviorthesis in haemophilic patients, 1 year after the 
procedure. Thirty-three men (36 knees) were studied, divided into two groups: a – injection of 
740 MBq of 153Sm-HA: 20 knees of 18 patients, with an average age of 21.4 ± 13.3 years (range: 
7–56 years) and medium Pettersson score of 5.3; b – injection of 185 MBq of 90Y-HA: 16 knees of 15 
patients, with an average age of 26.3 ± 10.3 (range: 7–51 years) and medium Pettersson score of 6.3. 
Episodes of haemarthrosis, use of clotting factors and pain intensity were evaluated before and 
after treatment, as well as improved joint mobility. The occurrence of side effects in the treatment 
was also considered. The chi-squared, Wilcoxon and Mann–Whitney tests were applied, with a sig-
nificance level of p ≤ 0.05. The occurrence of effusions decreased by 65.7% with the use of 153Sm-HA 
and 82.6% for 90Y-HA, without statistical significance between the groups (p = 0.632); pain reduc-
tion was 42.5% in group a and 30.7% in group b, again without statistical significance (p = 0.637). 
Increment in joint mobility was not significative for either group. Two cases of mild reactive syno-
vitis were observed in group a and one in group b, which had resolution without medical interven-
tion. Although the beta energy from 90Y is the more appropriate for knee synoviorthesis, the higher 
radioactivity levels of 153Sm is an alternative in locations that only produce this material [5].
8. Follow-up
This study aimed to evaluate synovectomy with 153Sm-hydroxyapatite (153Sm-HA) in syno-
vitis of the elbows and ankles of haemophilic patients. Synovectomy was performed using 
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185 MBq of 153Sm-HA in 166 joints (63 ankles and 84 elbows) of 82 haemophilic patients 
(average age 24.4 years) with follow-up of 12 and 42 months. Arthropathy was character-
ised by recurrent joint bleeding. Episodes of haemarthrosis, use of clotting factors and pain 
intensity were evaluated before and after treatment. Scintigraphic analyses and adverse 
effects were also considered. Statistics used p ≤ 0.05. The results indicated: (a) reduction in 
haemarthrosis was 78% and 68%, in elbows and 82% and 72% in ankles; (b) use of clotting 
factors was 80% and 70% for elbows, and 85% and 75% for ankles; (c) pain intensity was 
37% and 34% in elbows, and 61% and 57% in ankles, after 12 and 42 months, respectively. 
Among the 166 joints studied, three cases of mild reactive synovitis were observed in ankles 
and four in elbows, with no leakage in any of the cases. In conclusion, the use of 153Sm-HA 
in elbows and ankles was effective, very safe, minimally invasive and the results showed 
consistency at follow-up [6].
Another interesting aspect to consider is treatment repetition. We recommend this be done 
after 1 year, but a minimum interval of 6 months is permitted.
9. Final considerations
The radioactive material (153Sm) was aggregated with hydroxyapatite particles to ensure 
longer intra-articular retention without arterial-venous or peri-articular lymphatic leakage. 
When the two are separated, the advantage of the compound is that the carrier (hydroxyapa-
tite) enters the body’s metabolism because it is part of the bone matrix.
No escape (lymphatic or vascular) was detected with 153-samarium because when it sepa-
rates from the carrier (hydroxyapatite), it forms insoluble compounds with the synovial fluid 
that precipitate in the articulation; this permanence was confirmed by other previous studies 
[20] and by our controls (see Figure 3).
Scintigraphic images obtained after early and late-phase injection showed appropriate 
intra-articular distribution, as well as the absence of leakage to regional lymph nodes or 
other organs, or urinary elimination. The ability to obtain good-quality scintigraphic 
images is an advantage of 153Sm since gamma emission occurs in the energy amplitude 
of 100 keV. Another possible advantage is the mild reactive synovitis observed in all the 
studies, resolved without invasive medical intervention, possibly due to low beta energy 
penetration.
These studies are among the few that evaluate only the therapeutic effect of intra-articular 
radioactive material, since it is often administered in conjunction with corticosteroids. This 
creates bias in result analysis because corticosteroids are also used for the same purpose in 
the treatment of haemophilic arthropathy [11]. This combination has been called into ques-
tion [13] and is one of the reasons why we chose not to use it when beginning treatment [3], 
in addition to the lack of information in the literature characterising the nature of its effect as 
competitive, additive or synergistic.
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The reduction in haemarthrosis for ankles (82%), elbows (78%) and knees (65.7%) was simi-
lar to values recorded in other studies of haemophilic patients with different types of radio-
active material. A German revision pointed nine studies between 1982 and 1991 with good 
and excellent results for radiosynovectomy in 60–80% of the haemophilic arthropathy [9]. 
The findings presented in our studies also corroborate those summarised by Siegel et al. [25] 
regarding the benefits of radiosynoviorthesis, with an approximate 75% decrease in effusions, 
few adverse effects and better quality of life in 75% of the cases. This can be extended to 
shoulders and hips, which exhibited similar results to intermediate joints. Finally, it can be 
concluded that 153samarium labelled with hydroxyapatite is a useful tool in the treatment of 
chronic synovitis in haemophilic patients.
Figure 3. Knee scintigraphy showing good joint distribution and no leakage.
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